Health Care & Life Sciences » Biotechnology | Celldex Therapeutics Inc.

Celldex Therapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
81,550.00
118,080.00
127,197.00
128,530.00
93,031.00
Depreciation, Depletion & Amortization
2,945.00
3,401.00
4,011.00
4,092.00
5,310.00
Other Funds
4,931.00
1,171.00
4,311.00
-
-
Funds from Operations
75,347.00
107,665.00
109,774.00
106,476.00
87,726.00
Changes in Working Capital
7,678.00
6,128.00
10,887.00
6,560.00
12,205.00
Net Operating Cash Flow
67,669.00
101,537.00
98,887.00
113,036.00
99,931.00
Capital Expenditures
4,219.00
1,929.00
4,876.00
2,751.00
1,788.00
Sale of Fixed Assets & Businesses
21.00
-
-
4,592.00
-
Purchase/Sale of Investments
73,224.00
39,082.00
45,315.00
67,066.00
48,256.00
Net Investing Cash Flow
77,422.00
41,011.00
50,191.00
68,907.00
46,468.00
Issuance/Reduction of Debt, Net
11,029.00
-
-
-
-
Net Financing Cash Flow
289,599.00
1,171.00
193,151.00
14,482.00
51,290.00
Net Change in Cash
144,505.00
141,382.00
44,088.00
29,647.00
2,173.00
Free Cash Flow
71,888.00
103,466.00
103,763.00
115,787.00
101,719.00
Change in Capital Stock
295,697.00
-
188,840.00
14,482.00
51,290.00
Exchange Rate Effect
3.00
5.00
15.00
-
-

About Celldex Therapeutics

View Profile
Address
Perryville III Building
Hampton New Jersey 08827
United States
Employees -
Website http://www.celldex.com
Updated 09/14/2018
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.